SG Americas Securities LLC Acquires New Stake in Wave Life Sciences Ltd. (NASDAQ:WVE)

SG Americas Securities LLC acquired a new stake in Wave Life Sciences Ltd. (NASDAQ:WVE) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 108,814 shares of the company’s stock, valued at approximately $533,000. SG Americas Securities LLC owned 0.21% of Wave Life Sciences at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Invesco Ltd. acquired a new position in Wave Life Sciences during the 2nd quarter worth $84,000. State Board of Administration of Florida Retirement System grew its stake in Wave Life Sciences by 22.1% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 15,277 shares of the company’s stock worth $102,000 after purchasing an additional 2,761 shares in the last quarter. Parametric Portfolio Associates LLC acquired a new position in Wave Life Sciences during the 2nd quarter worth $103,000. Cambridge Investment Research Advisors Inc. acquired a new position in shares of Wave Life Sciences during the 2nd quarter worth about $107,000. Finally, ProShare Advisors LLC boosted its position in shares of Wave Life Sciences by 20.3% during the 2nd quarter. ProShare Advisors LLC now owns 18,690 shares of the company’s stock worth $124,000 after acquiring an additional 3,154 shares in the last quarter. Hedge funds and other institutional investors own 70.16% of the company’s stock.

Wave Life Sciences stock opened at $2.63 on Friday. Wave Life Sciences Ltd. has a fifty-two week low of $2.48 and a fifty-two week high of $12.17. The company has a market capitalization of $154.73 million, a P/E ratio of -1.12 and a beta of 0.49. The stock has a 50-day simple moving average of $3.63 and a 200-day simple moving average of $4.99.

Wave Life Sciences (NASDAQ:WVE) last posted its earnings results on Wednesday, November 10th. The company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.64) by $0.52. The firm had revenue of $36.42 million during the quarter, compared to analysts’ expectations of $10.70 million. During the same period in the previous year, the firm posted ($0.86) earnings per share. Sell-side analysts forecast that Wave Life Sciences Ltd. will post -2.21 earnings per share for the current year.

Several research analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Wave Life Sciences in a research report on Wednesday, September 29th. Zacks Investment Research raised Wave Life Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, November 16th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, Wave Life Sciences presently has an average rating of “Hold” and an average target price of $10.00.

About Wave Life Sciences

Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Featured Story: What’s a Black Swan?

Institutional Ownership by Quarter for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.